PR Newswire All News ReleasesQwen · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 04:04:00·⟳ 抓取 04:05:06 +1m06s·⚡ 决策 08-28 04:07:19 +2m13s·60.9 天前
Pomerantz律所发布Regeneron证券集体诉讼投资者提醒，核心事实为5月Fianlimab三期临床失败
本条Pomerantz律所提醒与72小时内已处理的SueWallSt(08-27 14:59 UTC)、Hagens Berman(08-26 22:17 UTC)、Levi & Korsinsky(08-26 14:12 UTC)三条记录为同一具体催化——均围绕Regeneron Fianlimab三期失败后的证券集体诉讼及9月14日首席原告截止日，无任何新增法院进展、监管动作、财务影响或临床事实。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rege…
不做 Regeneron Pharmaceuticals（REGN.US）
本条是既有证券集体诉讼的律所招揽/截止日提醒（第四份），核心临床失败和诉讼信息已于5月15日充分传播并定价，72小时内已有3条同类记录被处理为不做；无新增法院裁定、监管动作或可量化损害，不构成可交易催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pomerantz律所发布的投资者提醒是Regeneron证券集体诉讼的第四份律所招揽稿，核心事实（2026-05-15 Fianlimab三期PFS未达统计显著、股价下跌、集体诉讼已提交）已在5月中旬充分传播并被市场定价（当日跌9.82%），72小时内已有3条同类提醒被处理为不做。本条无新增金额、裁定、监管或临床事实，不构成可交易催化。
🔎 新鲜度:最早出现 2026-05-15 · 扩散 high · price-in 风险 high ↗
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 571 ms
{ - search_processed_events 成功 stock_tools HTTP · 11,555 ms
{"result": "search_processed_events:agent query=`regeneron class action lawsuit | regeneron fianlimab libtayo phase iii trial failure | regn securities fraud pomerantz`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.0/72 小时、11805 条本臂决策(完整)，返回 8 条候选。\n• 08-27 17:01 UTC(CST 08-28 01:01) [ticker] 不做 AMGN.US,AZN.US,REGN.U
原文全文
展开原文 · 2,485 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."
On this news, Regeneron's stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."
On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The class action concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until September 14, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Regeneron securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."
On this news, Regeneron's stock price fell $45.41 per share, or 6.21%, to close at $686.36 per share on April 29, 2026.
Then, on May 15, 2026, Regeneron issued a press release disclosing that the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)."
On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。